As a Free StocksGuide user, you can view scores for all 7,039 stocks worldwide.
8 Analysts have issued a Lyell Immunopharma Inc forecast:
8 Analysts have issued a Lyell Immunopharma Inc forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 0.06 0.06 |
0%
0%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -199 -199 |
3%
3%
|
|
| EBIT (Operating Income) EBIT | -215 -215 |
5%
5%
|
|
| Net Profit | -331 -331 |
58%
58%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.
| Head office | United States |
| CEO | Lynn Seely |
| Employees | 300 |
| Founded | 2018 |
| Website | lyell.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


